STAGE III ANAL CANCER AJCC V8
Clinical trials for STAGE III ANAL CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III ANAL CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III ANAL CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to fight metastatic anal cancer
Disease control OngoingThis phase 3 trial is testing whether adding the immunotherapy drug nivolumab to standard chemotherapy (carboplatin and paclitaxel) helps people with metastatic anal cancer live longer without their disease getting worse. About 205 adults with inoperable or recurrent anal cancer …
Matched conditions: STAGE III ANAL CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Immunotherapy after Chemo-Radiation may keep anal cancer at bay
Disease control OngoingThis phase III trial tests whether adding the immunotherapy drug nivolumab after standard combined modality therapy (chemo and radiation) can improve outcomes for patients with high-risk stage IIB-IIIC anal cancer. About 344 participants will receive nivolumab or a placebo. The m…
Matched conditions: STAGE III ANAL CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New trial tailors anal cancer treatment for people with HIV
Disease control OngoingThis phase 2 trial is testing whether adjusting treatment based on risk level can improve outcomes for people with HIV who have anal cancer. Low-risk patients receive standard chemotherapy and radiation, while high-risk patients also get the immunotherapy drug nivolumab after sta…
Matched conditions: STAGE III ANAL CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC